P588: Switching from infliximab originator to a first biosimilar is safe and effective: A single-centre series with through levels and anti-drug antibodies determinationECCO '18 Vienna
2018
P589: Adherence to medical treatment in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P592: Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experienceECCO '18 Vienna
2018
P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre studyECCO '18 Vienna
2018
P594: Patient-reported outcomes in pain and discharge correlate with objective assessments of perianal fistula remission in Crohn’s disease (CD)ECCO '18 Vienna
2018
P596: Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBDECCO '18 Vienna
2018
P597: Effectiveness and safety of vedolizumab therapy in an ulcerative colitis cohort with significant prior anti-TNF exposureECCO '18 Vienna
2018
P599: Short- and long-term outcome of minimally invasive approach for Crohn’s disease: Comparison between single incision, robotic-assisted and conventional laparoscopyECCO '18 Vienna
2018
P600: Clinical utility of anti-IFI16 seroreactivity in the response to anti-TNF therapy in IBDECCO '18 Vienna
2018
P601: Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST studyECCO '18 Vienna
2018
P602: Factors associated with discontinuation of initial and subsequent tumour necrosis factor inhibitors in a large paediatric inflammatory bowel disease observational cohortECCO '18 Vienna
2018
P603: Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel diseaseECCO '18 Vienna
2018
P605: Transanal minimally invasive proctectomy (TaMIP) in patients with Crohn’s disease: A cohort study from the TaTME international databaseECCO '18 Vienna
2018